المؤلفون: Patin EC; Targeted Therapy Team, The Institute of Cancer Research, London, UK. emmanuel.patin@icr.ac.uk., Nenclares P; Targeted Therapy Team, The Institute of Cancer Research, London, UK.; The Royal Marsden Hospital, London, UK., Chan Wah Hak C; Targeted Therapy Team, The Institute of Cancer Research, London, UK.; The Royal Marsden Hospital, London, UK., Dillon MT; Targeted Therapy Team, The Institute of Cancer Research, London, UK.; The Royal Marsden Hospital, London, UK., Patrikeev A; Targeted Therapy Team, The Institute of Cancer Research, London, UK., McLaughlin M; Targeted Therapy Team, The Institute of Cancer Research, London, UK., Grove L; Targeted Therapy Team, The Institute of Cancer Research, London, UK.; The Royal Marsden Hospital, London, UK., Foo S; Targeted Therapy Team, The Institute of Cancer Research, London, UK., Soliman H; The Royal Marsden Hospital, London, UK., Barata JP; The Royal Marsden Hospital, London, UK., Marsden J; The Royal Marsden Hospital, London, UK., Baldock H; Targeted Therapy Team, The Institute of Cancer Research, London, UK., Gkantalis J; Targeted Therapy Team, The Institute of Cancer Research, London, UK., Roulstone V; Targeted Therapy Team, The Institute of Cancer Research, London, UK., Kyula J; Targeted Therapy Team, The Institute of Cancer Research, London, UK., Burley A; Targeted Therapy Team, The Institute of Cancer Research, London, UK., Hubbard L; Targeted Therapy Team, The Institute of Cancer Research, London, UK., Pedersen M; Targeted Therapy Team, The Institute of Cancer Research, London, UK., Smith SA; Early Oncology R&D, AstraZeneca, Cambridge, UK., Clancy-Thompson E; Early Oncology R&D, AstraZeneca, Cambridge, UK., Melcher AA; Translational Immunotherapy Team, The Institute of Cancer Research, London, UK., Ono M; Department of Life Sciences, Imperial College London, London, UK., Rullan A; Targeted Therapy Team, The Institute of Cancer Research, London, UK.; The Royal Marsden Hospital, London, UK., Harrington KJ; Targeted Therapy Team, The Institute of Cancer Research, London, UK.; The Royal Marsden Hospital, London, UK.

المصدر: Nature communications [Nat Commun] 2024 Aug 13; Vol. 15 (1), pp. 6923. Date of Electronic Publication: 2024 Aug 13.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE

مواضيع طبية MeSH: Tumor Microenvironment*/immunology , Tumor Microenvironment*/radiation effects , Squamous Cell Carcinoma of Head and Neck*/immunology , Squamous Cell Carcinoma of Head and Neck*/radiotherapy , Squamous Cell Carcinoma of Head and Neck*/therapy , Squamous Cell Carcinoma of Head and Neck*/pathology , Immunotherapy*/methods , B7-H1 Antigen*/antagonists & inhibitors , B7-H1 Antigen*/metabolism , Ataxia Telangiectasia Mutated Proteins*/metabolism , Ataxia Telangiectasia Mutated Proteins*/antagonists & inhibitors, Animals ; Humans ; Mice ; Head and Neck Neoplasms/immunology ; Head and Neck Neoplasms/therapy ; Head and Neck Neoplasms/radiotherapy ; Cell Line, Tumor ; Immune Checkpoint Inhibitors/pharmacology ; Immune Checkpoint Inhibitors/therapeutic use ; NK Cell Lectin-Like Receptor Subfamily C/metabolism ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Programmed Cell Death 1 Receptor/metabolism ; CD8-Positive T-Lymphocytes/immunology ; Female ; T-Lymphocytes, Cytotoxic/immunology ; CD4-Positive T-Lymphocytes/immunology ; CD4-Positive T-Lymphocytes/radiation effects ; Mice, Inbred C57BL ; CD40 Antigens/metabolism ; CD40 Antigens/immunology ; CD40 Antigens/antagonists & inhibitors